A Phase II dose ranging, double‐blind, placebo‐controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left‐sided ulcerative colitis - VAN DEVENTER, S. J. H.; WEDEL, M. K.; BAKER, B. F.; XIA, S.; CHUANG, E.; MINER, P. B. (Alimentary pharmacology & therapeutics, 2006)
Keywords: Adult; Aged; Biological and medical sciences; Colitis, Ulcerative - drug therapy; Digestive system; Double-Blind Method; Drug Administration Schedule; Enema; Female; Gastroenterology. Liver. Pancreas. Abdomen; Gastrointestinal Agents - administration & dosage; Gastrointestinal Agents - adverse effects; Gastrointestinal Hemorrhage - etiology; Humans; Male; Medical sciences; Middle Aged; Oligodeoxyribonucleotides, Antisense - administration & dosage; Oligodeoxyribonucleotides, Antisense - adverse effects; Other diseases. Semiology; Pharmacology. Drug treatments; Phosphorothioate Oligonucleotides; Rectum; Recurrence; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Thionucleotides - administration & dosage; Thionucleotides - adverse effects; Treatment Outcome; Alicaforsen; Human; Left; Acute; Antisense oligonucleotide; Inflammatory disease; Enema; Exacerbation; Placebo; Dosage form; Double blind study; Sudden infant death syndrome; Digestive diseases; Intestinal disease; Dose; Ulcerative colitis